User Satisfaction with the Combined Oral Contraceptive Drospirenone 3 mg/Ethinylestradiol 20 mug (Yasminelle~R) in Clinical Practice A Multi-Country, Questionnaire-Based Study

摘要

Objective: To assess women's perception of a combined oral contraceptive(COC) containing drospirenone 3 mg/ethinylestradiol (EE) 20 ug administered in the conventional 21/7 regimen (drospirenone 3mg/EE 20mug 21/7 regimen [Yasminelle~R]) in clinical practice.Methods: This questionnaire-based study was performed in 12 European countries and included women who had been taking the drospirenone 3 mg/EE 20 mug 21/7 regimen COC for >3 months.Results: Of 16461 completed questionnaires, 12277 were from women who had been using the drospirenone 3 mg/EE 20 ug 21/7 regimen COC for >3 months - 34% of women were new users of COCs and 65% had switched from alternative contraceptive brands. The mean age of these respondents was approximately 27 years. Seventy percent of women who indicated that they had skin problems before taking the drospirenone 3 mg/EE 20 ug 21/7 regimen COC responded that their skin had improved with treatment (3030/4305). Sixty-nine percent of women who had switched to the drospirenone 3 mg/EE 20mug 21/7 regimen COC because of weight problems with their previous method, of contraception responded that they had experienced weight loss (1205/1745). Approximately 95% of respondents said they were satisfied with the drospirenone 3 mg/EE 20 ug 21/7 regimen COC. Moreover, 83% of respondents said they would recommend this COC to a friend. Conclusion: There were high levels of perceived satisfaction with the drospirenone 3 mg/EE 20 ug 21/7 regimen COC. The reported effects on weight loss (due to decreased water retention) and skin problems are consistent with the antimineralocorticoid and antiandrogenic benefits of drospirenone-containing COCs.